Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease

Journal of Internal Medicine

Volumn 266, Issue 3, 2009, Pages 221-231

  Nilsson, J ^a   Fredrikson, G N ^a,b   Bjorkbacka H ^a   Chyu, K Y ^c   Shah, P K ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cardiovascular clinical research; Vaccine

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B ANTIBODY; ATHEROSCLEROSIS VACCINE; B7 ANTIGEN; BI 204; CD28 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CVX 210H; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 2 RECEPTOR ALPHA; LIPOPROTEIN; MALONALDEHYDE; MALONDIALDEHYDE MODIFIED APOLIPOPROTEIN B IMMUNOGLOBULIN G1; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; GENE REARRANGEMENT; HUMAN; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TH1 CELL; VACCINATION;

ANIMALS; ANTIGENS; ATHEROSCLEROSIS; AUTOIMMUNITY; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL; MODELS, ANIMAL; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 68949118039     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02150.x     Document Type: Review

References (67)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 : 1685 95.
2. Libby P. Inflammation in atherosclerosis. Nature 2002 420 : 868 74.
3. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001 104 : 503 16.
4. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001 1 : 135 45.
5. Bjorkbacka H, Kunjathoor VV, Moore KJ et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004 10 : 416 21.
6. Michelsen KS, Wong MH, Shah PK et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 2004 101 : 10679 84.
7. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005 115 : 3149 56.
8. Bjorkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol 2006 17 : 527 33.
9. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol 2007 18 : 492 9.
10. Farooq M, Haq I, Qureshi AS. Cardiovascular risks of COX inhibition: current perspectives. Expert Opin Pharmacother 2008 9 : 1311 9.
11. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002 111 : 927 30.
12. Hou B, Reizis B, DeFranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 2008 29 : 272 82.
13. Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 2008 263 : 464 78.
14. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000 102 : 2919 22.
15. Tupin E, Nicoletti A, Elhage R et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004 199 : 417 22.
16. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res 2005 96 : 427 34.
17. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A 2000 97 : 7464 9.
18. Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2004 109 : 2009 15.
19. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006 86 : 515 81.
20. Frostegard J, Ulfgren AK, Nyberg P et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999 145 : 33 43.
21. Uyemura K, Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996 97 : 2130 8.
22. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in apoE knock-out mice. J Clin Invest 1997 99 : 2752 61.
23. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A 2005 102 : 1596 601.
24. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999 85 : e17 24.
25. Pinderski LJ, Fischbein MP, Subbanagounder G et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002 90 : 1064 71.
26. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-{beta} signaling in T cells accelerates atherosclerosis. J Clin Invest 2003 112 : 1342 50.
27. Mallat Z, Gojova A, Brun V et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 2003 108 : 1232 7.
28. Shah PK, Chyu KY, Fredrikson GN, Nilsson J. Immunomodulation of atherosclerosis with a vaccine. Nat Clin Pract Cardiovasc Med 2005 2 : 639 46.
29. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 2000 247 : 371 80.
30. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002 8 : 1218 26.
31. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994 14 : 32 40.
32. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development - clinical and animal studies. Clin Chim Acta 2004 348 : 1 8.
33. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995 92 : 3893 7.
34. Paulsson G, Zhou X, Tornquist E, Hansson GK. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000 20 : 10 7.
35. De Palma R, Del Galdo F, Abbate G et al. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation 2006 113 : 640 6.
36. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 1995 92 : 821 5.
37. Ameli S, Hultgardh-Nilsson A, Regnstrom J et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996 16 : 1074 9.
38. Nilsson J, Calara F, Regnstrom J et al. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol 1997 30 : 1886 91.
39. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998 18 : 1972 82.
40. George J, Afek A, Gilburd B et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998 138 : 147 52.
41. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001 21 : 108 14.
42. Chyu KY, Reyes OS, Zhao X et al. Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (-/-) mice. Atherosclerosis 2004 176 : 27 35.
43. Chou MY, Hartvigsen K, Hansen LF et al. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med 2008 263 : 479 88.
44. Faria-Neto JR, Chyu KY, Li X et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006 189 : 83 90.
45. Binder CJ, Horkko S, Dewan A et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003 9 : 736 43.
46. Caligiuri G, Khallou-Laschet J, Vandaele M et al. Phosphorylcholine- targeting immunization reduces atherosclerosis. J Am Coll Cardiol 2007 50 : 540 6.
47. Fredrikson GN, Hedblad B, Berglund G et al. Identification of immune responses against aldehyde-modified peptide sequences in apo B-100 associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003 23 : 872 8.
48. Fredrikson GN, Soderberg I, Lindholm M et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003 23 : 879 84.
49. Fredrikson GN, Andersson L, Soderberg I et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity 2005 38 : 171 9.
50. Chyu KY, Zhao X, Reyes OS et al. Immunization using an apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochem Biophys Res Commun 2005 338 : 1982 9.
51. Schiopu A, Bengtsson J, Soderberg I et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004 110 : 2047 52.
52. Strom A, Fredrikson GN, Schiopu A et al. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis 2006 190 : 298 305.
53. Schiopu A, Frendeus B, Jansson B et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 2007 50 : 2313 8.
54. Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah PK, Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007 194 : e188 92.
55. Sjogren P, Fredrikson GN, Samnegard A et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 2008 29 : 2218 26.
56. Fredrikson GN, Bjorkbacka H, Soderberg I, Ljungcrantz I, Nilsson J. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J Intern Med 2008 264 : 563 70.
57. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000 101 : 455 8.
58. Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc Med 2007 17 : 113 8.
59. Ait-Oufella H, Salomon BL, Potteaux S et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006 12 : 178 80.
60. Afek A, George J, Gilburd B et al. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 2000 14 : 115 21.
61. Xu Q, Dietrich H, Steiner HJ et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992 12 : 789 99.
62. Xu Q, Willeit J, Marosi M et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993 341 : 255 9.
63. Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol 2002 40 : 1333 8.
64. Maron R, Sukhova G, Faria AM et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002 106 : 1708 15.
65. van Puijvelde GH, van Es T, van Wanrooij EJ et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007 27 : 2677 83.
66. van Puijvelde GH, Hauer AD, de Vos P et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006 114 : 1968 76.
67. Fernando MM, Stevens CR, Walsh EC et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008 4 : e1000024.